Home » Reports » Investor Presentations » Avacta Affimer Innovative Immunotherapies Presentation February 2019
Avacta Group

Avacta Affimer Innovative Immunotherapies Presentation February 2019

Avacta plc (LON: AVCT) Affimer Innovative Immunotherapies Presentation Feb 2019 by CEO Alastair Smith.

Avacta’s principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability. Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta plc has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.

Join us on our new LinkedIn page

Follow us on LinkedIn